Markets | | | Autozone Sets New All-Time High After Smash Earnings
Autozone (AZO) is not a cheap stock. Trading near $1250 per share it is one of the pricier issues you will find on the market today. When it comes to value though, value is where you find it and Autozone has value. That’s why it’s bre... Read the Full Story |
|
From Our PartnersSimple Options Trading for Beginners retails on Amazon for $19.95 and has 4 out of 5 stars. It was written by a stock market trading veteran with over 44 years of experience. Because of a special promotion, this book is 100% FREE for you today. | | So get it here now... |
|
Markets | | |
Disney (NYSE:DIS) stock is up nearly 40% in 2019. And I believe it’s about to go even higher. For much of 2019, the story around Disney has focused on the launch of its streaming service, Disney+. Disney stock started to climb in late March as investors began to price in the effect that this... Read the Full Story |
|
Markets | | | Here are some small and large-cap stocks with interesting technical setups in play. It’s well worth keeping them on a watchlist in case shares breakout. Check out last week’s Technical Watchlist here.
Minerals Technologies (NYSE:MTX)
Despite selling into their Q3 earnings at the end of... Read the Full Story |
|
|
Markets | | | While trading commission rates have been falling, the major online brokers took a momentous leap to zero-commission stock trading in 2019 causing an industry-wide paradigm shift forcing literally all online brokers to adopt the zero-commission model Read the Full Story |
|
Markets | | | recent word from Needham sank another nail in the coffin, downgrading to the equivalent of a “sell” rating and issuing another disastrous choice: add a new subscriber tier or lose millions of customers. Read the Full Story |
|
From Our PartnersWhat if you could buy one tiny stock today for $10 - at the center of a growing tech industry - that experts believe will explode a massive 77,400%?
Wall Street legend Paul Mampilly recently identified this as the stock of the century.
Buying up a handful of shares of this small company now could change your life and even make you millions. | | Click here now. |
|
The Early Bird Stock Of The Day Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California. | | View Today's Stock Pick |
|
